CoChat

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition

Open access
Wilson, Catherine, Nicholes, Katrina, Bustos, Daisy, Lin, Eva, Song, Qinghua, Stephan, Jean-Philippe, Kirkpatrick, Donald S., Settleman, Jeff · 2014 · Oncotarget
Cited by 145

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

// Catherine Wilson 1 , Katrina Nicholes 2 , Daisy Bustos 2 , Eva Lin 1 , Qinghua Song 3 , Jean-Philippe Stephan 2 , Donald S. Kirkpatrick 2 and Jeff Settleman 1 1 Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 2 Department of Discovery Protein Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 3 Department of Discovery Nonclinical Biostatistics, Genentech, 1 DNA Way, South San Francisco, CA Correspondence: Jeff Settleman, email: // Keywords : EMT, Src, drug resistance, dasatinib, cancer Received : July 19, 2014 Accepted : August 26, 2014 Published : August 27, 2014 Abstract Epithelial to mesenchymal transition (EMT) is a key process in embryonic development and has been associated with cancer metastasis and drug resistance. For example, in EGFR mutated non-small cell lung cancers (NSCLC), EMT has been associated with acquired resistance to the EGFR inhibitor erlotinib. Moreover, “EGFR-addicted” cancer cell lines induced to undergo EMT become erlotinib-resistant in vitro . To identify potential therapeutic vulnerabilities specifically within these mesenchymal, erlotinib-resistant cells, we performed a small molecule screen of ~200 established anti-cancer agents using the EGFR mutant NSCLC HCC827 cell line and a corresponding mesenchymal derivative line. The mesenchymal cells were more resistant to most tested agents; however, a small number of agents showed selective growth inhibitory activity against the mesenchymal cells, with the most potent being the Abl/Src inhibitor, dasatinib. Analysis of the tyrosine phospho-proteome revealed several Src/FAK pathway kinases that were differentially phosphorylated in the mesenchymal cells, and RNAi depletion of the core Src/FAK pathway components in these mesenchymal cells caused apoptosis. These findings reveal a novel role for Src/FAK pathway kinases in drug resistance and identify dasatinib as a potential therapeutic for treatment of erlotinib resistance associated with EMT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2397

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Wilson, C., Nicholes, K., Bustos, D., Lin, E., Song, Q., Stephan, J.-P., Kirkpatrick, D. S., & Settleman, J.
Venue
Oncotarget
Published
2014-08-27
Volume
5
Issue
17
Pages
7328-7341
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2133555426
Cited by
145
References
12
FWCI
9.62
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.